Thermo Fisher Scientific Inc.
TMO · NYSE
9/27/2025 | 6/28/2025 | 3/29/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $175,482,720 | $154,329,840 | $189,060,480 | $199,167,552 |
| - Cash | $1,982,000 | $4,579,000 | $4,134,000 | $4,009,000 |
| + Debt | $35,680,000 | $35,229,000 | $34,189,000 | $32,775,000 |
| Enterprise Value | $209,180,720 | $184,979,840 | $219,115,480 | $227,933,552 |
| Revenue | $11,122,000 | $10,855,000 | $10,364,000 | $11,395,000 |
| % Growth | 2.5% | 4.7% | -9% | – |
| Gross Profit | $4,652,000 | $4,048,000 | $4,245,000 | $4,467,000 |
| % Margin | 41.8% | 37.3% | 41% | 39.2% |
| EBITDA | $2,838,000 | $2,798,000 | $2,628,000 | $3,068,000 |
| % Margin | 25.5% | 25.8% | 25.4% | 26.9% |
| Net Income | $1,616,000 | $1,617,000 | $1,507,000 | $1,830,000 |
| % Margin | 14.5% | 14.9% | 14.5% | 16.1% |
| EPS Diluted | 4.27 | 4.28 | 3.98 | 4.78 |
| % Growth | -0.2% | 7.5% | -16.7% | – |
| Operating Cash Flow | $2,239,000 | $1,399,000 | $723,000 | $3,290,000 |
| Capital Expenditures | -$404,000 | -$294,000 | -$362,000 | -$480,000 |
| Free Cash Flow | $1,835,000 | $1,105,000 | $361,000 | $2,810,000 |